NCT03244020
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Enrolling by Invitation
PHASE4Ages 18+InterventionalPreventionMassachusetts General HospitalInvestigator-initiated
~2,868 participants
Updated 2025-10-03 on ClinicalTrials.gov
What's tested:Aspirin 325mgEnoxaparin 40Mg/0.4mL Prefilled Syringe
At a glance
Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Venous thromboembolism
Measured over Up to 3 or 6 months post operatively for bone/soft tissue sarcomas and metastatic osseous disease, respectively
Conditions
Where it's being run
10 sites across 8 statesMassachusetts3
California1
Florida1
Louisiana1
Maryland1
Missouri1
New Jersey1
Ohio1
Study leadership
- Santiago A Lozano-Calderon, MD, PhD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Venous thromboembolismUp to 3 or 6 months post operatively for bone/soft tissue sarcomas and metastatic osseous disease, respectively
Deep venous thrombosis; pulmonary embolus